Kainos Laboratories, Inc. (4556) AI Stock Analysis

• Market Cap: ¥5.30B
• Dividend Yield: 2.47%
• Average Volume (3M): 1.10K
• Price to Earnings (P/E): 8.6
• Beta (1Y): 0.23
• Revenue Growth: 5.38%
• EPS Growth: -7.04%
• Country: JP
• Employees: 133
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 43.57
• Shares Outstanding: 4,558,860
• 10 Day Avg. Volume: 710
• 30 Day Avg. Volume: 1,103
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,442.00
• Price Target Upside: 11.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 84 Outperform
• Price Target: ¥1,442.00 ▲(11.35% Upside)

Kainos Laboratories, Inc. receives a strong overall score due to its excellent financial performance and attractive valuation. The company's robust financial position supports its growth trajectory, while its low P/E ratio and solid dividend yield make it appealing for value and income investors. Technical analysis presents a neutral to slightly bullish outlook, contributing to the overall score.

Kainos Laboratories, Inc. Business Overview & Revenue Model

Company Description

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Kainos Laboratories, Inc. generates revenue through the sale of its pharmaceutical products, which include diagnostic reagents and therapeutic drugs. The company invests in research and development to create innovative medical solutions that meet the needs of healthcare providers and patients. Revenue streams are primarily driven by its product sales to hospitals, clinics, and laboratories. Additionally, Kainos Laboratories may engage in strategic partnerships and collaborations with other healthcare organizations and research institutions to expand its market reach and enhance its product offerings. These partnerships could also contribute to revenue through joint ventures or co-development projects.

Kainos Laboratories, Inc. Financial Statement Overview

Summary

Kainos Laboratories, Inc. is performing exceptionally well across all financial verticals. The company shows strong revenue growth and profitability, backed by excellent operational efficiency. Its balance sheet is robust with low leverage and high equity. Cash flow metrics are impressive, demonstrating effective cash management strategies. Overall, Kainos Laboratories is in a stable financial position, supporting its growth trajectory in the medical instruments and supplies industry.

Income Statement

Kainos Laboratories has demonstrated consistent revenue growth with a Revenue Growth Rate of 4.93% from 2024 to 2025. The Gross Profit Margin is 49.28% for 2025, indicating strong profitability. The Net Profit Margin has improved to 12.08%, reflecting efficient cost management. EBIT and EBITDA margins are robust at 15.52% and 17.66%, respectively, highlighting the company's operational efficiency.

Balance Sheet

The company maintains a strong financial position with a low Debt-to-Equity Ratio of 0.09, indicating conservative leverage. The Equity Ratio is high at 77.12%, showing a strong capital structure. Return on Equity (ROE) is healthy at 9.46%, reflecting effective use of equity capital to generate profits.

Cash Flow

Kainos Laboratories exhibits strong cash flow performance with a Free Cash Flow Growth Rate of 78.44% from 2024 to 2025. The Operating Cash Flow to Net Income Ratio is favorable at 1.10. The Free Cash Flow to Net Income Ratio stands at 0.99, indicating efficient conversion of earnings into free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.31B	5.06B	4.92B	4.61B	4.26B
Gross Profit	2.61B	2.55B	2.51B	2.41B	2.31B
EBITDA	936.87M	1.05B	994.26M	924.87M	763.42M
Net Income	641.02M	637.97M	568.17M	512.33M	417.40M
Balance Sheet
Total Assets	8.79B	8.59B	8.12B	7.57B	6.96B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.17B	3.02B	2.68B	2.24B
Total Debt	629.49M	862.97M	941.10M	947.61M	1.00B
Total Liabilities	2.01B	2.32B	2.45B	2.37B	2.30B
Stockholders Equity	6.78B	6.27B	5.67B	5.20B	4.66B
Cash Flow
Free Cash Flow	633.30M	354.87M	536.81M	463.19M	518.06M
Operating Cash Flow	704.78M	430.58M	544.51M	604.36M	591.25M
Investing Cash Flow	-71.30M	-72.83M	-10.33M	-141.19M	-117.16M
Financing Cash Flow	-411.04M	-203.73M	-191.14M	-31.25M	-194.61M

Kainos Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1295.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Positive. The current price of 1295 is above the 20-day moving average (MA) of 1284.00, above the 50-day MA of 1273.76, and above the 200-day MA of 1225.05, indicating a bullish trend. The MACD of 4.55 indicates Positive momentum. The RSI at 57.77 is Neutral, neither overbought nor oversold. The STOCH value of 37.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4556.

Kainos Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4556	84 Outperform	¥5.30B	8.57	―	2.47%	5.38%	-7.04%
7980	76 Outperform	¥5.76B	8.65	9.11%	1.85%	5.45%	0.23%
7730	75 Outperform	¥127.68B	23.39	12.01%	3.01%	5.82%	-20.09%
7979	73 Outperform	¥71.97B	17.70	10.12%	2.58%	6.82%	-1.08%
7743	67 Neutral	¥16.53B	14.82	6.05%	2.75%	2.38%	-48.68%
7702	60 Neutral	¥11.19B	-40.36	0.22%	3.71%	3.36%	-310.49%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%